Product Information
PHENTERMINE 37.5 MG CAPSULE is a generic product labeled by Sunrise Pharmaceutical Inc., priced at $0.1051 per EA under NDC 11534015903. Its NADAC has been published 386 times since May 15, 2019.
FDA first approved this application on Sep 25, 2014. Its Orange Book therapeutic-equivalence code is AA.
Strength
37.5 mg/1
Manufacturer
Sunrise Pharmaceutical Inc.NDC
11534015903
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205017FDA Approved
9/25/2014
TE Code
AA
On Market Since
1/24/2017
Pharmacological Classes
Price Statistics
The NADAC for PHENTERMINE 37.5 MG CAPSULE has been published 386 times since May 15, 2019, and over the history we have for it it has declined 6.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1051 per EA |
|---|---|
| All-time high | $0.1421 (Apr 10, 2024) |
| All-time low | $0.0688 (Dec 23, 2020) |
| 52-week high | $0.1051 |
| 52-week low | $0.0794 |
| Median price | $0.0994 |
| Average price | $0.1001 |
| Largest weekly change | +64.3% (Nov 22, 2023) |
| Weeks tracked | 386 |
| Tracking since | May 15, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the phentermine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sunrise Pharmaceutical Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
phentermine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHENTERMINE 37.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE 37.5 MG CAPSULE, manufactured by Sunrise Pharmaceutical Inc., is $0.1051 per EA (NDC 11534015903), effective Sep 30, 2026.
How has the price of PHENTERMINE 37.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PHENTERMINE 37.5 MG CAPSULE has declined 6.5%. It has been tracked across 386 weekly CMS publications since May 15, 2019.
What are the highest and lowest recorded NADAC prices for PHENTERMINE 37.5 MG CAPSULE?
Since May 15, 2019, the NADAC for PHENTERMINE 37.5 MG CAPSULE has ranged from a low of $0.0688 (Dec 23, 2020) to a high of $0.1421 (Apr 10, 2024), with a median of $0.0994 per EA.
Are there cheaper alternatives to PHENTERMINE 37.5 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of PHENTERMINE 37.5 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PHENTERMINE 37.5 MG CAPSULE?
PHENTERMINE 37.5 MG CAPSULE (NDC 11534015903) is labeled by Sunrise Pharmaceutical Inc., and CMS classifies it as a generic product.